Lantheus/$LNTH
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Lantheus
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
Ticker
$LNTH
Sector
Primary listing
Employees
808
Headquarters
Website
Lantheus Metrics
BasicAdvanced
$3.5B
13.71
$3.77
0.15
-
Price and volume
Market cap
$3.5B
Beta
0.15
52-week high
$115.01
52-week low
$47.25
Average daily volume
2.1M
Financial strength
Current ratio
4.29
Quick ratio
3.685
Long term debt to equity
57.339
Total debt to equity
52.751
Interest coverage (TTM)
22.00%
Profitability
EBITDA (TTM)
494.005
Gross margin (TTM)
63.75%
Net profit margin (TTM)
17.82%
Operating margin (TTM)
28.46%
Effective tax rate (TTM)
28.00%
Revenue per employee (TTM)
$1,880,000
Management effectiveness
Return on assets (TTM)
13.34%
Return on equity (TTM)
24.71%
Valuation
Price to earnings (TTM)
13.714
Price to revenue (TTM)
2.347
Price to book
3.01
Price to tangible book (TTM)
5.58
Price to free cash flow (TTM)
8.373
Free cash flow yield (TTM)
11.94%
Free cash flow per share (TTM)
6.18
Growth
Revenue change (TTM)
5.75%
Earnings per share change (TTM)
-37.87%
3-year revenue growth (CAGR)
31.80%
10-year revenue growth (CAGR)
17.59%
3-year earnings per share growth (CAGR)
101.44%
10-year earnings per share growth (CAGR)
10.82%
What the Analysts think about Lantheus
Analyst ratings (Buy, Hold, Sell) for Lantheus stock.
Bulls say / Bears say
Lantheus’s acquisitions of Evergreen Theragnostics and Life Molecular Imaging broadened its radiopharmaceutical portfolio by adding products such as OCTEVY™ and Neuraceq®, diversifying revenues across oncology and neurology (Reuters)
FDA acceptance of a new piflufolastat F18 PSMA PET imaging agent formulation, with a PDUFA date of March 6, 2026, could improve production efficiency and strengthen Lantheus’s position in the PSMA PET imaging market (Reuters)
Analyst sentiment is still strong, with 12 of 13 covering Lantheus (LNTH) issuing “buy” ratings and a consensus 12-month price target of $130, pointing to substantial potential upside from current prices (Reuters)
Increased competition in the PSMA PET market led to a 4.1% decline in Q2 revenue to $378 million and a 12.8% drop in adjusted EPS to $1.57, missing analyst expectations and highlighting short-term pressure on key products (Reuters)
Lantheus revised its full-year 2025 guidance downward, now projecting $1.475 billion to $1.51 billion in revenue and $5.50 to $5.70 in adjusted EPS, compared to previous estimates of $1.55 billion to $1.585 billion in revenue and $6.60 to $6.70 in adjusted EPS, signaling increased difficulty reaching prior targets (Reuters)
LNTH shares dropped 7.4% to $91.03 after announcing the up to $1 billion acquisition of Evergreen Theragnostics, as investors showed concern over short-term cash outflows and limited EPS accretion, expected about 18 months post-close (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.
Lantheus Financial Performance
Revenues and expenses
Lantheus Earnings Performance
Company profitability
Lantheus News
AllArticlesVideos
Law Offices of Howard G. Smith Encourages Lantheus Holdings, Inc. (LNTH) Investors To Inquire About Securities Fraud Class Action
Business Wire16 hours ago
Law Offices of Frank R. Cruz Encourages Lantheus Holdings, Inc. (LNTH) Investors To Inquire About Securities Fraud Class Action
Business Wire16 hours ago
Securities Fraud Investigation Into Lantheus Holdings, Inc. (LNTH) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
Business Wire4 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Lantheus stock?
Lantheus (LNTH) has a market cap of $3.5B as of September 16, 2025.
What is the P/E ratio for Lantheus stock?
The price to earnings (P/E) ratio for Lantheus (LNTH) stock is 13.71 as of September 16, 2025.
Does Lantheus stock pay dividends?
No, Lantheus (LNTH) stock does not pay dividends to its shareholders as of September 16, 2025.
When is the next Lantheus dividend payment date?
Lantheus (LNTH) stock does not pay dividends to its shareholders.
What is the beta indicator for Lantheus?
Lantheus (LNTH) has a beta rating of 0.15. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.